[PDF][PDF] Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.
JR Berenson, A Lichtenstein, L Porter… - Journal of Clinical …, 1998 - researchgate.net
JR Berenson, A Lichtenstein, L Porter, MA Dimopoulos, R Bordoni, S George, A Lipton…
Journal of Clinical Oncology, 1998•researchgate.netPurpose: To determine the efficacy and safety of 21 monthly cycles of pamidronate therapy
in patients with advanced multiple myeloma. Patients and Methods: Patients with stage III my-
eloma and at least one lytic lesion received either placebo or pamidronate 90 mg
intravenously administered as a 4-hour infusion monthly for 21 cycles. At study entry, the
patients were stratified according to whether they were to receive first-line (stratum 1) or
second-line (stratum 2) antimyeloma chemotherapy. Skeletal events (pathologic fracture …
in patients with advanced multiple myeloma. Patients and Methods: Patients with stage III my-
eloma and at least one lytic lesion received either placebo or pamidronate 90 mg
intravenously administered as a 4-hour infusion monthly for 21 cycles. At study entry, the
patients were stratified according to whether they were to receive first-line (stratum 1) or
second-line (stratum 2) antimyeloma chemotherapy. Skeletal events (pathologic fracture …
Purpose: To determine the efficacy and safety of 21 monthly cycles of pamidronate therapy in patients with advanced multiple myeloma.
Patients and Methods: Patients with stage III my-eloma and at least one lytic lesion received either placebo or pamidronate 90 mg intravenously administered as a 4-hour infusion monthly for 21 cycles. At study entry, the patients were stratified according to whether they were to receive first-line (stratum 1) or second-line (stratum 2) antimyeloma chemotherapy. Skeletal events (pathologic fracture, radiation or surgery to bone, and spinal cord compression) and hypercalcemia were assessed monthly.
Results: The results of the first nine previously re-ported cycles are extended to 21 cycles. Of the 392 randomized patients, efficacy could be evaluated in 198 who received pamidronate and 179 who received placebo. After 21 cycles, the proportion of patients who
researchgate.net